Sharps Technology INC 8-K filings

Sharps Technology is reminding shareholders to vote in favor of a reverse stock split to maintain its Nasdaq listing and avoid delisting to the OTC Markets.

Sharps Technology, Inc. received a delisting notice from Nasdaq due to its failure to maintain a minimum bid price of $1.00 per share, and the company plans to appeal the decision.

Sharps Technology successfully closed a $20 million public offering to fund debt repayment, working capital, and general corporate activities.

Sharps Technology, Inc. amended its bylaws on January 21, 2025, to clarify that one-third of stockholders constitutes a quorum for stockholder meetings.

Sharps Technology, Inc. held its annual meeting, electing directors, ratifying the accounting firm, and approving the 2024 Equity Incentive Plan.

Sharps Technology, Inc. has entered into subscription agreements to sell 248,430 shares of common stock at $1.95 per share, raising $484,438 before fees.

Sharps Technology announces significant sales agreements and expansion plans for its Hungary manufacturing facility, projecting substantial revenue growth.

Sharps Technology has signed agreements to sell its entire existing inventory of SecureGard syringes to a major European healthcare network, with new orders expected to begin in Q2 2025.

Sharps Technology, Inc. has amended its bylaws, effective November 4, 2024, to change the quorum requirement for stockholder meetings to one-third of stockholders.

Sharps Technology will implement a 1-for-22 reverse stock split effective October 15, 2024, to comply with Nasdaq's minimum bid price requirement.

Sharps Technology stockholders have approved a proposal to authorize a reverse stock split of its common stock within a range of 1-for-8 to 1-for-22.

Sharps Technology is urging shareholders to vote in favor of a reverse stock split to regain compliance with NASDAQ's minimum bid price requirement and avoid delisting.

Sharps Technology, Inc. has finalized a $3.5 million secured bridge loan financing with institutional investors, involving the sale of notes and common stock or pre-funded warrants.

Sharps Technology has received approval from Nasdaq to maintain its listing, contingent on completing a reverse stock split to address a bid price deficiency.

Sharps Technology, Inc. has amended its Articles of Incorporation to increase the authorized number of common stock shares from 100 million to 500 million.

Sharps Technology has entered into a five-year supply agreement with Stericare Solutions, LLC for 520 million units of 10ml PP Sologard syringes, expected to generate over $50 million in revenue.

Sharps Technology stockholders have approved an increase in authorized shares and a reverse stock split, along with authorization for discounted non-public offerings.

Sharps Technology is facing delisting from the Nasdaq Capital Market due to its stock price falling below $1.00, but has requested a hearing to appeal the decision, while also gaining shareholder approval for a share increase and reverse stock split.

Sharps Technology's CEO is urging shareholders to vote in favor of three proposals that are deemed vital for the company's continued growth and strategic initiatives.

Sharps Technology is urging its shareholders to vote in favor of three key proposals at the upcoming special meeting on July 15th, which are critical for the company's future operations and growth.

Sharps Technology raised approximately $1.18 million through the sale of common stock and the exercise of warrants.

Sharps Technology has received a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes, marking a significant step towards commencing production at their newly acquired facility.

Sharps Technology has placed a $1 million escrow deposit to secure exclusive rights to purchase InjectEZ assets, paving the way for a $200 million sales agreement and entry into the prefillable syringe market.

Sharps Technology raised approximately $2.2 million through a combination of common stock sales and warrant exercises.

Sharps Technology, Inc. has issued new warrants to purchase common stock after reaching an agreement with existing warrant holders to reduce their exercise price.

Sharps Technology has finalized an asset purchase and sales agreement, positioning them to become a major player in the U.S. prefillable syringe market with a guaranteed $200 million in sales over five years.

Sharps Technology, Inc. has issued new warrants to purchase common stock after reaching an agreement with existing warrant holders to reduce their exercise price.

Sharps Technology is strategically positioned to benefit from recent FDA recalls and increased tariffs on Chinese-made syringes, according to a shareholder letter from the company's CEO.

Sharps Technology, Inc. has entered into a five-year purchase agreement with Nephron for a minimum of $188.5 million in syringes and amended its asset purchase agreement with InjectEZ, LLC.

Sharps Technology enters into a cooperative sales and distribution agreement with Roncadelle Operations s.r.l. and a logistics agreement with Owens & Minor, while terminating its previous distribution agreement with Nephron Pharmaceuticals.